Desmoid tumors: Insights from DGHO 2025
Management of desmoid tumors
What are the latest advances in the care of people with desmoid tumors? Bernd Kasper (Mannheim University Medical Centre, Germany) and Maya Niethard (University Hospital Regensburg, Germany) discussed their perspectives at Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) 2025 in Cologne, Germany. Watch updates on:
- Clinical presentation and diagnostic assessment
- Understanding the patient’s point of view
- Advances in the desmoid tumor treatment landscape
- The surgical management of desmoid tumors
Content is available with German or English captions. Die Inhalte sind mit deutschen oder englischen Untertiteln verfügbar.
Unmet needs and diagnostic assessment
What is the most significant unmet need in the management of desmoid tumors? Kasper gives his view, and describes the clinical presentation and techniques for diagnostic assessment of this rare disease. View transcript. Hier das Transkript anzeigen.
Patient perspective and communication
Kasper considers the lived experience of people with desmoid tumors, and the importance of communicating both benefits and risks of the latest treatments. View transcript. Hier das Transkript anzeigen.
Advances in the treatment landscape
How is the treatment landscape of desmoid tumors evolving? Kasper reviews the available treatments for desmoid tumors, the paradigm shift from surgical approaches, and what he expects over the next 5 years. View transcript. Hier das Transkript anzeigen..
A surgeon’s perspective on management
What role does surgery play in the management of desmoid tumors? Niethard discusses the place of surgeons in the multidisciplinary team and the key considerations when deciding whether surgery should be recommended to a patient. View transcript. Hier das Transkript anzeigen.
Meet the experts
Bernd Kasper, MD, PhD
Bernd Kasper works at the Sarcoma Unit of the Mannheim Cancer Center (MCC) at the Mannheim University Medical Center, University of Heidelberg, Germany. Kasper has dedicated his professional life to patient care and research in soft tissue sarcomas, desmoid-type fibromatosis, and gastrointestinal stromal tumors. His clinical practice focuses exclusively on these disease entities. He is head of the study center of the German Interdisciplinary Sarcoma Group (GISG) and is active in national and international study groups (AIO, EORTC).
Disclosures: Advisory roles or expert testimonies for Ayala, Bayer, Boehringer Ingelheim, Deciphera, Parabilis Medicines, PharmaMar, and SpringWorks Therapeutics. Honoraria from Bayer and PharmaMar. Funding for scientific research from Cogent Biosciences, Immunome, PharmaMar, and SpringWorks Therapeutics.
Maya Niethard, MD
Maya Niethard is Head of the Sarcoma Center and the Department of Orthopedic Oncology at the University Hospital Regensburg, Germany.
Disclosures: No disclosures provided at the time of publication.
of interest
are looking at
saved
next event
Development of this education content has been supported by a grant/funding from SpringWorks Therapeutics. The content has been independently developed by EPG Health with no input or influence from SpringWorks Therapeutics.
Copyright © 2011 Michael Bonert, MD, FRCPC. Image licensed under CC BY-SA 3.0.